The Insulin Price Cap Mirage The $35 per month cap on insulin prescriptions has failed to deliver significant improvements in affordability, despite widespread fanfare.
Millions of people continue to struggle to afford their lifesaving medication. Recent surveys and studies indicate that pharmaceutical greed remains a major obstacle to insulin accessibility.
According to the Yale Diabetes Center's research, nearly one quarter of patients treated there in 2024 were rationing insulin due to cost concerns – a rate comparable to that seen in 2017.